JUNSNasdaqPharmaceutical PreparationsFiscal year ends December 31

JUPITER NEUROSCIENCES, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$2.75−0.15 (-5.34%)

Close on Oct 19, 2026

Market cap: $1.53M
P/E (TTM): –
Dividend yield: –

JUPITER NEUROSCIENCES, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Revenue	0.02	0	–
Cost of Revenue	0.00	–	–
Gross Profit	0.02	–	–
Research & Development	2.09	0.49	0.95
Selling, General & Admin	6.84	–	–
General & Administrative	6.84	2.60	2.92
Operating Expenses	8.93	3.09	3.87
Operating Income	-8.91	-3.09	-3.87
Interest Expense	0.07	0.25	0.22
Interest & Investment Income	–	0.01	0.00
Other Non-Operating Income	0.26	0.65	-0.91
Net Income	-8.64	-2.44	-4.78
EPS (Basic)(per share)	-18.75	-6.00	-13.50
EPS (Diluted)(per share)	-18.75	-6.00	-13.50
Shares Outstanding (Basic, Weighted)(shares)	0.46	0.38	0.35
Shares Outstanding (Diluted, Weighted)(shares)	0.46	0.38	0.35

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 80.6%
Operating margin: -45016.4%
Net margin: -42206.9%
Return on equity, FY2025: -738.8%

Financial strength

Current ratio: 0.66
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 39.2%

Valuation

P/E ratio: –
Price to sales: 70.35
Price to book: –
Dividend yield: –